RP-HPLC method for the determination of losartan potassium and ramipril in combined dosage form

Indian Journal of Pharmaceutical Sciences

Volumn 72, Issue 1, 2010, Pages 108-111

  Rao, K Srinivasa ^a   Srinivas, K ^a  

^a ROLAND INSTITUTE OF PHARMACEUTICAL SCIENCES   (India)

Author keywords

Losartan potassium; Ramipril; RP HPLC; Validation

Indexed keywords

LORAM 5; LOSARTAN POTASSIUM; LOSARTAN POTASSIUM PLUS RAMIPRIL; RAMIPRIL; UNCLASSIFIED DRUG;

ARTICLE; DRUG DETERMINATION; DRUG DOSAGE FORM; FLOW RATE; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TABLET FORMULATION;

EID: 77951695882     PISSN: 0250474X     EISSN: 19983743     Source Type: Journal    
DOI: 10.4103/0250-474X.62243     Document Type: Article

References (14)

1. Brenner BM, Cooper ME, de Zeeuw D. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869
2. Sleight P, Yusuf S, Pogue J. Blood-pressure reduction and cardiovascular risk in the HOPE study. Lancet 2001;358:2130-2131
3. Wright JT Jr, Bakris G, Greene T. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. J Am Med Assn 2002;288:2421-2431
4. McCarthy KE, Wang Q, Tsai EW, Gilbert RE, Ip DP, Brooks MA. Determination of losartan and its degradants in COZAAR tablets by reversed-phase high-performance thin-layer chromatography. J Pharm Biomed Anal 1998;17:671-677
5. Williams RC, Alasandro MS, Fasone VL, Boucher RJ, Edwards JF. Comparison of liquid chromatography, capillary electrophoresis and super-critical fl uid chromatography in the determination of Losartan Potassium drug substance in Cozaar tablets. J Pharm Biomed Anal 1996;14:1539-1546
6. Polinko M, Riffel K, Song H, Lo MW. Simultaneous determination of losartan and EXP3174 in human plasma and urine utilizing liquid chromatography/tandem mass spectrometry. J Pharm Biomed Anal 2003;33:73-84.
7. Furtek CI, Lo MW. Simultaneous determination of a novel angiotensin II receptor blocking agent, losartan, and its metabolite in human plasma and urine by high-performance liquid chromatography. J Pharm Biomed Anal 1997;15:1021-1029
8. Soldner A, Spahn-Langguth H, Mutschler E. HPLC assays to simultaneously determine the angiotensin-AT1 antagonist losartan as well as its main and active metabolite EXP 3174 in biological material of humans and rats. J Pharm Biomed Anal 1998;16:863-873
9. Yeung PK, Jamieson A, Smith GJ, Fice D, Pollak PT. Determination of plasma concentrations of losartan in patients by HPLC using solid phase extraction and UV detection. Int J Pharm 2000;204:17-22.
10. Iwasa T, Takano T, Hara K, Kamei T. Method for the simultaneous determination of losartan and its major metabolite, EXP-3174, in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry. J Chromatogr B Biomed Sci Appl 1999;734:325-330
11. Lastra OC, Lemus IG, Sanchez HJ, Perez RF. Development and validation of an UV derivative spectrophotometric determination of Losartan potassium in tablets. J Pharm Biomed Anal 2003;33:175-180
12. Ansari M, Kazemipour M, Khosravi F, Baradaran M. A comparative study of fi rst-derivative spectrophotometry and high-performance liquid chromatography applied to the determination of losartan potassium in tablets. Chem Pharm Bull 2004;52:1166-1170
13. Prabhakar AH, Giridhar R. A rapid colorimetric method for the determination of Losartan potassium in bulk and in synthetic mixture for solid dosage form. J Pharm Biomed Anal 2002;27:861-866
14. Gandhimathi M. HPLC determination of losartan pottassium and ramipril in tablets. Indian drugs 2004;41:120-122